	US 12,453,750 B2
	Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases
Itschak Lamensdorf, Ness Ziona (IL); and Yona Levy, Jerusalem (IL)
Assigned to ALVIT LCS PHARMA LTD., Tel Aviv (IL)
Appl. No. 17/440,981
Filed by ALVIT LCS PHARMA LTD., Tel Aviv (IL)
PCT Filed Mar. 20, 2020, PCT No. PCT/IL2020/050337 § 371(c)(1), (2) Date Sep. 20, 2021, PCT Pub. No. WO2020/188577, PCT Pub. Date Sep. 24, 2020.
Claims priority of provisional application 62/821,461, filed on Mar. 21, 2019.
Prior Publication US 2022/0160801 A1, May 26, 2022
Int. Cl. A61K 36/07 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 36/062 (2006.01); A61K 36/074 (2006.01); A61K 36/185 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)

CPC A61K 36/07 (2013.01) [A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 36/062 (2013.01); A61K 36/074 (2013.01); A61K 36/185 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01)]

7 Claims

1. A composition useful for treating inflammatory diseases characterized by dysregulation of at least one pro-inflammatory member selected from the group consisting of TNF-α, IL-6, and NO, in a mammalian subject, wherein said composition comprises a combination of a) a cannabis-derived compound; b) a medicinal mushroom; and, c) a pharmaceutical acceptable excipient, said cannabis-derived compound is THC, and said medicinal mushroom is Cordyceps M (militaris) or Cordyceps Cs-4 (sinensis) wherein the w/w or molar ratio between said THC and said medicinal mushroom is between 1:12 and 1:318.